オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 70.225 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350 - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 35.11 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350 - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 140.45 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; titanium dioxide; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350 - sildenafil is indicated for the treatment of erectile dysfunction in adult males.,it is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 70.24 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; macrogol 8000; hyprolose; titanium dioxide; magnesium stearate; colloidal anhydrous silica; hypromellose - sildenafil is indicated for the treatment of erectile dysfunction in adult males. sildenafil is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 70.24 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; hyprolose; macrogol 8000; hypromellose; croscarmellose sodium; microcrystalline cellulose; titanium dioxide - sildenafil is indicated for the treatment of erectile dysfunction in adult males. sildenafil is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 35.12 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: hypromellose; croscarmellose sodium; titanium dioxide; macrogol 8000; magnesium stearate; hyprolose; colloidal anhydrous silica; microcrystalline cellulose - sildenafil is indicated for the treatment of erectile dysfunction in adult males. sildenafil is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 35.12 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; macrogol 8000; magnesium stearate; hypromellose - sildenafil is indicated for the treatment of erectile dysfunction in adult males. sildenafil is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: macrogol 8000; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; hypromellose; titanium dioxide; hyprolose - sildenafil is used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil has not been evaluated in patients currently on bosentan therapy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; calcium hydrogen phosphate; croscarmellose sodium; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 28.096 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; hyprolose; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - ? to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. ? efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. ? the efficacy of sildenafil has not been evaluated in patients currently on bosentan therapy.